AMLX insider transaction filings
Amylyx Pharmaceuticals, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen AMLX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Mazzariello Gina — Chief Legal Officer | Grant/award (A): 21,284 @ $0 | EDGAR |
| 2026-08-20 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Grant/award (A): 60,039 @ $0 | EDGAR |
| 2026-08-20 | 4 | FRATES JAMES M — Chief Financial Officer | Grant/award (A): 22,807 @ $0 | EDGAR |
| 2026-08-20 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Grant/award (A): 60,039 @ $0 | EDGAR |
| 2026-08-20 | 4 | Bedrosian Camille L — Chief Medical Officer | Grant/award (A): 22,807 @ $0 | EDGAR |
| 2026-07-13 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 15,000 @ $18.32 · Sale (S): 15,000 @ $17.61 | EDGAR |
| 2026-06-08 | 4 | Zeiher Bernhardt G — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Firestone Karen — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | FONTEYNE PAUL R. — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Quimi Daphne — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | MILNE GEORGE M JR — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Firestone Karen — Director | Purchase (P): 3,800 @ $13.51 | EDGAR |
| 2026-03-09 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Grant/award (A): 248,865 @ $0 · Grant/award (A): 373,295 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Mazzariello Gina — Chief Legal Officer | Grant/award (A): 74,660 @ $0 · Grant/award (A): 111,990 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Grant/award (A): 248,865 @ $0 · Grant/award (A): 373,295 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Bedrosian Camille L — Chief Medical Officer | Grant/award (A): 95,990 @ $0 · Grant/award (A): 143,985 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | FRATES JAMES M — Chief Financial Officer | Grant/award (A): 95,990 @ $0 · Grant/award (A): 143,985 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 29,282 @ $14.47 | EDGAR |
| 2026-03-04 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 29,282 @ $14.48 | EDGAR |
| 2026-03-04 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 6,844 @ $14.52 | EDGAR |
| 2026-03-04 | 4 | Bedrosian Camille L — Chief Medical Officer | Sale (S): 6,461 @ $14.58 | EDGAR |
| 2026-03-04 | 4 | FRATES JAMES M — Chief Financial Officer | Sale (S): 7,909 @ $14.52 | EDGAR |
| 2026-02-25 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 3,419 @ $14.14 | EDGAR |
| 2026-02-04 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 15,500 @ $14.68 | EDGAR |
| 2026-02-04 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 3,448 @ $14.65 | EDGAR |
| 2026-02-04 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 15,500 @ $14.69 | EDGAR |
| 2026-02-04 | 4 | FRATES JAMES M — Chief Financial Officer | Sale (S): 3,557 @ $14.65 | EDGAR |
| 2026-01-20 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Option exercise (M): 197,182 @ $7.57 · Sale (S): 136,193 @ $13.59 · Option exercise (M): 2,818 @ $7.57 · Sale (S): 1,974 @ $13.83 · Option exercise (M): 197,182 (derivative) @ $0 · Option exercise (M): 2,818 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Option exercise (M): 197,153 @ $7.57 · Sale (S): 136,193 @ $13.58 · Option exercise (M): 2,847 @ $7.57 · Sale (S): 1,995 @ $13.89 · Option exercise (M): 197,153 (derivative) @ $0 · Option exercise (M): 2,847 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | MILNE GEORGE M JR — Director | Gift (G): 17,780 @ $0 | EDGAR |
| 2026-01-08 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 7,715 @ $11.09 | EDGAR |
| 2026-01-08 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 7,715 @ $11.09 | EDGAR |
| 2026-01-08 | 4 | FRATES JAMES M — Chief Financial Officer | Sale (S): 3,326 @ $11.11 | EDGAR |
| 2025-12-23 | 4 | Firestone Karen — Director | Purchase (P): 8,100 @ $12.45 | EDGAR |
| 2025-12-03 | 4 | Bedrosian Camille L — Chief Medical Officer | Sale (S): 6,580 @ $14.35 | EDGAR |
| 2025-10-02 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 29,775 @ $14.37 · Sale (S): 200 @ $15.01 | EDGAR |
| 2025-10-02 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 8,828 @ $14.58 | EDGAR |
| 2025-10-02 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 29,733 @ $14.34 · Sale (S): 200 @ $15.00 | EDGAR |
| 2025-10-02 | 4 | Bedrosian Camille L — Chief Medical Officer | Sale (S): 12,039 @ $14.58 | EDGAR |
| 2025-10-02 | 4 | FRATES JAMES M — Chief Financial Officer | Sale (S): 10,558 @ $14.65 | EDGAR |
| 2025-08-14 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 15,000 @ $8.07 · Sale (S): 15,000 @ $8.34 | EDGAR |
| 2025-06-09 | 4 | FONTEYNE PAUL R. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Firestone Karen — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Zeiher Bernhardt G — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Quimi Daphne — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | MILNE GEORGE M JR — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | Mazzariello Gina — Chief Legal Officer | Gift (G): 1,000 @ $0 | EDGAR |
| 2025-04-02 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 9,192 @ $3.48 | EDGAR |
| 2025-04-02 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 21,490 @ $3.47 | EDGAR |
| 2025-04-02 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 21,490 @ $3.46 | EDGAR |
Recent 8-K events — Amylyx Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-18 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AMLX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →